Ocugen's valuation remains tethered to a high-risk, unproven modifier gene therapy platform that lacks a stable, product-driven commercial revenue stream. The company's reliance on non-recurring milestone payments and aggressive stock-based compensation create...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.07-31.3% vs -$0.05 | $1M+67.4% vs $888,833 |
Q2 2026 May 5, 2026 | -$0.06-20.0% vs -$0.05 | $2M+266.9% vs $417,833 |
Q2 2026 Mar 4, 2026 | -$0.06+0.0% vs -$0.06 | $193,000-118.0% vs $1M |
Q4 2025 Nov 5, 2025 | -$0.07-21.7% vs -$0.06 | $2M+298.2% vs $440,000 |
Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion.
Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet needs in ophthalmology. I assign OCGN a Buy rating, citing strong clinical data, upcoming pivotal trial catalysts, and sufficient cash runway, despite high commercial and execution risk. Key upcoming catalysts include Phase 3 data for OCU400 and OCU410ST (Stargardt) in 2027 and a Phase 3 trial for OCU410 now FDA-cleared.
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for GA secondary to dry age-related macular degeneration (dAMD). The Company also highlighted the recent FDA RMAT designation for OCU410, which supports a potential accelerated development and review pathway for the program.
Benchmark OCGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ocugen, Inc. (OCGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.00 | $339.11M | -4.35 | 8.83% | -1537.41% | -776.89% | — | |
| $12.96 | $1.09B | -3.83 | — | — | -159.32% | — | |
| $2.69 | $412.81M | -1.49 | 25.39% | -157.32% | -196.63% | — | |
| $24.37 | $2.51B | -30.09 | 120.01% | -54.75% | -7.7% | — | |
| $12.33 | $1.38B | -3.24 | 16.92% | -672.16% | -57.79% | — | |
| $55.76 | $5.38B | -8.62 | -89.97% | -3368.72% | -24.39% | — |
Ocugen, Inc. (OCGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ocugen, Inc. (OCGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 13, 2026·SEC
Jun 11, 2026·SEC
Get notified when OCGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ocugen, Inc. (OCGN) stock FAQ — growth, dividends, profitability & financials explained
Ocugen, Inc. (OCGN) reported $4.6M in revenue for fiscal year 2025. This represents a 17515% increase from $0.0M in 2012.
Ocugen, Inc. (OCGN) grew revenue by 8.8% over the past year. This is steady growth.
Ocugen, Inc. (OCGN) reported a net loss of $81.8M for fiscal year 2025.
Ocugen, Inc. (OCGN) has a return on equity (ROE) of -776.9%. Negative ROE indicates the company is unprofitable.
Ocugen, Inc. (OCGN) had negative free cash flow of $61.4M in fiscal year 2025, likely due to heavy capital investments.
